Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison

Aim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a...

Full description

Bibliographic Details
Main Authors: Teruo Inamoto, Takanobu Ubai, Takeshi Nishida, Yutaka Fujisue, Yoji Katsuoka, Haruhito Azuma
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2013-01-01
Series:Urology Annals
Subjects:
Online Access:http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=Inamoto
id doaj-9e9290fad6f94f259a636fbd825a0bb1
record_format Article
spelling doaj-9e9290fad6f94f259a636fbd825a0bb12020-11-24T23:08:37ZengWolters Kluwer Medknow PublicationsUrology Annals0974-77960974-78342013-01-015171210.4103/0974-7796.106873Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparisonTeruo InamotoTakanobu UbaiTakeshi NishidaYutaka FujisueYoji KatsuokaHaruhito AzumaAim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a randomized, active-controlled, open-label, monocenter study. Thirty-eight, NMIBC patients were treated sequentially, in a random order, with low-dose Tokyo 172 strain and regular dose Connaught strain, receiving each therapy for 6 weeks. A total of 18 and 20 patients were randomly assigned to a Tokyo 172 strain arm and a Connaught strain arm, respectively. Complication, morbidity, and recurrence-free survival (RFS) after each treatment were compared. Results: There was no significant difference in the 1-year RFS rate in patients treated with Tokyo 172 strain and Connaught strain (72.2% vs. 83.5%, respectively; P = 0.698). There were no significant differences in adverse events between the arms. Severe adverse events (>Grade 3) were seen in 15% of the Connaught strain group while no severe adverse events were observed as a result of Tokyo 172 strain. Conclusion: Our results indicated that low-dose Tokyo 172 strain decreased adverse events although it was not significant, and the RFS difference was not statistically significant between the two arms. Further investigation is warranted.http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=InamotoBacillus Calmette-Guérinbladder cancerintravesical instillationTokyo 172 strain
collection DOAJ
language English
format Article
sources DOAJ
author Teruo Inamoto
Takanobu Ubai
Takeshi Nishida
Yutaka Fujisue
Yoji Katsuoka
Haruhito Azuma
spellingShingle Teruo Inamoto
Takanobu Ubai
Takeshi Nishida
Yutaka Fujisue
Yoji Katsuoka
Haruhito Azuma
Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
Urology Annals
Bacillus Calmette-Guérin
bladder cancer
intravesical instillation
Tokyo 172 strain
author_facet Teruo Inamoto
Takanobu Ubai
Takeshi Nishida
Yutaka Fujisue
Yoji Katsuoka
Haruhito Azuma
author_sort Teruo Inamoto
title Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
title_short Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
title_full Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
title_fullStr Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
title_full_unstemmed Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective comparison
title_sort comparable effect with minimal morbidity of low-dose tokyo 172 strain compared with regular dose connaught strain as an intravesical bacillus calmette-guérin prophylaxis in nonmuscle invasive bladder cancer: results of a randomized prospective comparison
publisher Wolters Kluwer Medknow Publications
series Urology Annals
issn 0974-7796
0974-7834
publishDate 2013-01-01
description Aim: The aim was to compare patients′ morbidity and response of bacillus Calmette-Guérin (BCG) prophylaxis after the intravesical instillation of low-dose Tokyo 172 strain and regular dose Connaught strain in patients with nonmuscle invasive bladder cancer (NMIBC). Patients and Methods: This was a randomized, active-controlled, open-label, monocenter study. Thirty-eight, NMIBC patients were treated sequentially, in a random order, with low-dose Tokyo 172 strain and regular dose Connaught strain, receiving each therapy for 6 weeks. A total of 18 and 20 patients were randomly assigned to a Tokyo 172 strain arm and a Connaught strain arm, respectively. Complication, morbidity, and recurrence-free survival (RFS) after each treatment were compared. Results: There was no significant difference in the 1-year RFS rate in patients treated with Tokyo 172 strain and Connaught strain (72.2% vs. 83.5%, respectively; P = 0.698). There were no significant differences in adverse events between the arms. Severe adverse events (>Grade 3) were seen in 15% of the Connaught strain group while no severe adverse events were observed as a result of Tokyo 172 strain. Conclusion: Our results indicated that low-dose Tokyo 172 strain decreased adverse events although it was not significant, and the RFS difference was not statistically significant between the two arms. Further investigation is warranted.
topic Bacillus Calmette-Guérin
bladder cancer
intravesical instillation
Tokyo 172 strain
url http://www.urologyannals.com/article.asp?issn=0974-7796;year=2013;volume=5;issue=1;spage=7;epage=12;aulast=Inamoto
work_keys_str_mv AT teruoinamoto comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
AT takanobuubai comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
AT takeshinishida comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
AT yutakafujisue comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
AT yojikatsuoka comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
AT haruhitoazuma comparableeffectwithminimalmorbidityoflowdosetokyo172straincomparedwithregulardoseconnaughtstrainasanintravesicalbacilluscalmetteguerinprophylaxisinnonmuscleinvasivebladdercancerresultsofarandomizedprospectivecomparison
_version_ 1725613249216380928